Eli Lilly's Weight Loss Portfolio

This is a news story, published by Yahoo Finance, that relates primarily to Novo Nordisk news.

Novo Nordisk news

For more Novo Nordisk news, you can click here:

more Novo Nordisk news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

weight loss drug market

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest obesity drug market news, oral weight loss drug news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

weight loss drugs

The Motley Fool

•

Here's why you should buy Viking Therapeutics instead of Eli Lilly

Summary

Nutrition label

67% Informative

Eli Lilly and Novo Nordisk dominate the weight loss drug market, but competition may be on the horizon.

One up-and-coming player is attracting a lot of attention thanks to its fantastic clinical trial results.

Viking Therapeutics' first weight loss candidate may soon launch phase 3 trials, the last stage of development prior to regulatory review.

The 10 stocks that made the cut could produce monster returns in the coming years .

Consider when Nvidia made this list on April 15, 2005 ... if you invested $ 1,000 at the time of our recommendation, you’d have $ 896,358 ! The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002 .

VR Score

Informative language

Neutral language

Article tone

semi-formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful